Research field (1)：
Healthcare management, medical sociology
Research theme for competitive and other funds (12)：
2021 - 2024 医薬品効能の各国間差異発生要因の解析による行政判断への影響要因の検討
2020 - 2023 Study on drug utilization, research and development of intractable disease treatment using the database
2017 - 2020 Drug information and prescription for older adults
2016 - 2019 添付文書警告欄の検証に基づく効果的な医薬品安全性情報提供の研究
2016 - 2019 Study on effective drug safety information based on investigation of boxed warning
2014 - 2017 How to develop a good patient information leaflet of a medicine
2012 - 2016 Assessment of regulatory efforts to facilitate the approval of off-label drugs
2012 - 2013 有害物質暴露等の対応を目的とした医薬品確保対策の国際比較
2011 - 2013 Regulatory science research on drug develpment, review, and post-marketing regulation
2008 - 2011 親水性基と疎水性基の組合せによる新規Cdc25A阻害剤リード骨格の探索
2008 - 2010 Development of novel class of Cdc25A inhibitor by combination of hydrophilic and hydrophobic group
2006 - 2008 Total synthesis of Salinosporamide A, a potent proteasome inhibitor
Show all
Papers (60)：
Rumiko Shimazawa, Masayuki Ikeda. Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech). Journal of pharmaceutical policy and practice. 2021. 14. 1. 46-46
Rumiko Shimazawa, Masayuki Ikeda. Approvals of type 2 diabetes drugs tested in cardiovascular outcome trials: A tripartite comparison. British Journal of Clinical Pharmacology. 2021. 87. 10. 3938-3948
Rumiko Shimazawa, Masayuki Ikeda. Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan. Expert review of molecular diagnostics. 2020. 20. 6. 601-610
